Skip Nav Destination
Issues
Perspective
Featured Articles
Clinical Trials
Molecular Oncology, Markers, Clinical Correlates
Clinical and Biomarker Correlates of Androgen-Independent, Locally Aggressive Prostate Cancer with Limited Metastatic Potential
Vasily J. Assikis; Kim-Anh Do; Sijin Wen; Xuemei Wang; Jeong Hee Cho-Vega; Shawn Brisbay; Remigio Lopez; Christopher J. Logothetis; Patricia Troncoso; Christos N. Papandreou; Timothy J. McDonnell
Variability in the Degree of Expression of Phosphorylated IκBα in Chronic Lymphocytic Leukemia Cases With Nodal Involvement
Antonia Rodríguez; Nerea Martínez; Francisca I. Camacho; Elena Ruíz-Ballesteros; Patrocinio Algara; Juan-Fernando García; Javier Menárguez; Tomás Alvaro; Manuel F. Fresno; Fernando Solano; Manuela Mollejo; Carmen Martin; Miguel A. Piris
Experimental Therapeutics, Preclinical Pharmacology
Components of the Cell Death Machine and Drug Sensitivity of the National Cancer Institute Cell Line Panel
Phyllis A. Svingen; David Loegering; Joe Rodriquez; Xue Wei Meng; Peter W. Mesner, Jr.; Susan Holbeck; Anne Monks; Stan Krajewski; Dominic A. Scudiero; Edward A. Sausville; John C. Reed; Yuri A. Lazebnik; Scott H. Kaufmann
Regular Articles
Clinical Trials
A Phase I and Pharmacodynamic Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed, Refractory, or High-Risk Acute Leukemia
Brenda W. Cooper; Gareth J. Veal; Tomas Radivoyevitch; Michael J. Tilby; Howard J. Meyerson; Hillard M. Lazarus; Omer N. Koc; Richard J. Creger; Graham Pearson; Geoff M. Nowell; David Gosky; Stephen T. Ingalls; Charles L. Hoppel; Stanton L. Gerson
Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance
Ricky A. Sharma; Stephanie A. Euden; Sharon L. Platton; Darren N. Cooke; Aisha Shafayat; Heather R. Hewitt; Timothy H. Marczylo; Bruno Morgan; David Hemingway; Simon M. Plummer; Munir Pirmohamed; Andreas J. Gescher; William P. Steward
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Effect of Human Papillomavirus-16 Infection on CD8+ T-Cell Recognition of a Wild-Type Sequence p53264–272 Peptide in Patients with Squamous Cell Carcinoma of the Head and Neck
Nicky Sirianni; Patrick K. Ha; Mattias Oelke; Joseph Califano; William Gooding; William Westra; Theresa L. Whiteside; Wayne M. Koch; Jonathan P. Schneck; Albert DeLeo; Robert L. Ferris
The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients
Xiao-Ying Shang; Hong-Song Chen; Hua-Gang Zhang; Xue-Wen Pang; Huan Qiao; Ji-Run Peng; Li-Ling Qin; Ran Fei; Ming-Hui Mei; Xi-Sheng Leng; Sacha Gnjatic; Gerd Ritter; Andrew J. G. Simpson; Lloyd J. Old; Wei-Feng Chen
Experimental Therapeutics, Preclinical Pharmacology
The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2′-deoxycytidine
Wade G. Alleman; Ray L. Tabios; Gadisetti V. R. Chandramouli; Olga N. Aprelikova; Carlos Torres-Cabala; Arnulfo Mendoza; Craig Rodgers; Nikolai A. Sopko; W. Marston Linehan; James R. Vasselli
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Kevin J. Hamblett; Peter D. Senter; Dana F. Chace; Michael M. C. Sun; Joel Lenox; Charles G. Cerveny; Kim M. Kissler; Starr X. Bernhardt; Anastasia K. Kopcha; Roger F. Zabinski; Damon L. Meyer; Joseph A. Francisco
HMMC-1: A Humanized Monoclonal Antibody With Therapeutic Potential Against Müllerian Duct-Related Carcinomas
Shiro Nozawa; Daisuke Aoki; Katsumi Tsukazaki; Nobuyuki Susumu; Motoko Sakayori; Nao Suzuki; Atsushi Suzuki; Rie Wakita; Makio Mukai; Yuko Egami; Kyoko Kojima-Aikawa; Isao Ishida; Frederic Belot; Ole Hindsgaul; Minoru Fukuda; Michiko N. Fukuda
Abrogation of Head and Neck Squamous Cell Carcinoma Growth by Epidermal Growth Factor Receptor Ligand Fused to Pseudomonas Exotoxin Transforming Growth Factor α-PE38
Sufi M. Thomas; Qing Zeng; Michael W. Epperly; William E. Gooding; Ira Pastan; Qing Cheng Wang; Joel Greenberger; Jennifer Rubin Grandis
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.